Home Cart Sign in  
Chemical Structure| 524-30-1 Chemical Structure| 524-30-1

Structure of Fraxin
CAS No.: 524-30-1

Chemical Structure| 524-30-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fraxin protects HUVECs from oxidative stress, enhances urate excretion partly by inhibiting mURAT1 or mGLUT9 in kidney of hyperuricemic mice. It is a natural product isolated and purified from the bark of Fraxinus brngeana DC..

Synonyms: Fraxoside; Fraxetol 8-glucoside; Fraxetin-8-O-glucoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fraxin

CAS No. :524-30-1
Formula : C16H18O10
M.W : 370.31
SMILES Code : COC(C=C1C=C2)=C(O)C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)=C1OC2=O
Synonyms :
Fraxoside; Fraxetol 8-glucoside; Fraxetin-8-O-glucoside
MDL No. :MFCD00010093
InChI Key :CRSFLLTWRCYNNX-QBNNUVSCSA-N
Pubchem ID :5273568

Safety of Fraxin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SK-N-SH cells 10 and 20 µM 48 hours Evaluate the antiviral effect of Fraxin on HSV-1 infection, results showed Fraxin inhibited HSV-1 GFP expression at 20 µM. Antioxidants (Basel). 2021 Oct 18;10(10):1638
glomerular mesangial cells (GMCs) 20, 40, 60 μM 24 hours Fraxin significantly inhibited HG-induced FN and ICAM-1 expression and promoted the activation of the Nrf2 signaling pathway Front Pharmacol. 2022 Mar 24;13:853383
MNT1 cells 20, 40, 80 μM 24 hours To evaluate the protective effect of Fraxin against H2O2-induced apoptosis. Results showed that Fraxin pretreatment significantly reduced the apoptosis rate induced by H2O2 and decreased nuclear pyknosis and fragmentation. Heliyon. 2023 Aug 3;9(8):e18929
MNT1 cells 0, 40, 80, 160, 320 μM 48 hours To evaluate the effect of Fraxin on melanogenesis. Results showed that Fraxin treatment reduced melanin content and downregulated melanogenesis-related proteins (TYR, TYRP1, DCT, and RAB27A). Heliyon. 2023 Aug 3;9(8):e18929
MNT1 cells 2.5 to 640 μM 24, 48, and 72 hours To evaluate the effect of Fraxin on MNT1 cell viability. Results showed that low concentrations of Fraxin (2.5 to 320 μM) had no significant effect on cell viability, while 640 μM Fraxin significantly reduced cell viability after 48 and 72 hours of treatment. Heliyon. 2023 Aug 3;9(8):e18929
Hep G2 cells 1-100 μg/mL 12 hours To evaluate the protective effect of Fraxin against t-BHP-induced hepatotoxicity. Results showed that Fraxin significantly reduced t-BHP-induced cytotoxicity and decreased reactive oxygen species (ROS) production. Molecules. 2017 Apr 6;22(4):587

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Db/db mice Diabetic nephropathy model Oral 25, 50, 100 mg/kg 6 days per week for 8 weeks Fraxin significantly improved renal dysfunction and pathological changes of renal fibrosis in diabetic db/db mice, and upregulated the expression of Cx43 and Nrf2/ARE pathway-related proteins Front Pharmacol. 2022 Mar 24;13:853383
Zebrafish Zebrafish embryos Treatment in culture medium 40, 80, 160, 320 μM Daily replacement of culture medium for 5 days To verify the inhibitory effect of Fraxin on melanogenesis in zebrafish. Results showed that Fraxin treatment significantly reduced the density of melanin granules in the tails of zebrafish in a concentration-dependent manner. Heliyon. 2023 Aug 3;9(8):e18929
Sprague-Dawley rats CCl4-induced hepatotoxicity model Oral 5, 10, 50 mg/kg Five consecutive days To evaluate the protective effect of Fraxin against CCl4-induced hepatotoxicity. Results showed that Fraxin significantly reduced serum AST and ALT levels, increased glutathione (GSH) levels, and decreased malondialdehyde (MDA) levels in the liver. Molecules. 2017 Apr 6;22(4):587
Mice Reserpine-induced depressive-like disorder model Oral 50 mg/kg Once daily for 10 days To evaluate the effects of Fraxin on reserpine-induced depressive-like behaviors. The results showed that Fraxin significantly reduced immobility time in the forced swim test and tail suspension test and increased activity in the center zone in the open field test. Additionally, Fraxin decreased plasma corticosterone concentrations, reduced mRNA levels of pro-inflammatory cytokines in the hippocampus, and increased the expression of pCREB and BDNF in the hippocampus. Front Behav Neurosci. 2021 Jun 17;15:650833
Swiss albino BALB/c mice LPS-induced cytokine storm model Intraperitoneal injection 120 mg/kg Single dose, lasted for 24 hours To evaluate the prophylactic effect of Fraxin on LPS-induced cytokine storm. Results showed that Fraxin significantly reduced the levels of IL-1β, IL-6, and TNF-α, and alleviated pathological damage in lung and kidney tissues. Iran J Med Sci. 2024 May 1;49(5):322-331
Wistar albino rats Cisplatin-induced hepatotoxicity model Oral 40 mg/kg Once daily for one week To evaluate the protective effect of Fraxin against cisplatin-induced hepatotoxicity. Results showed that Fraxin significantly reduced oxidative stress parameters (e.g., MDA), enhanced antioxidant parameters (e.g., GSH, SOD, CAT, and GPx), and alleviated histopathological damage and inflammatory responses (e.g., TNF-α and Caspase-3 expression). Iran J Basic Med Sci. 2020 Nov;23(11):1382-1387

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.70mL

0.54mL

0.27mL

13.50mL

2.70mL

1.35mL

27.00mL

5.40mL

2.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories